Minister vows ‘improvements' to Internal Market Act
Mr Alexander however made clear that ministers have not considered scrapping the Internal Market Act (IMA), with the Scottish Government branding the results of the Westminster review 'completely unacceptable'.
Angus Robertson, the Scottish Government's Constitution Secretary, insisted the legislation – which Holyrood has twice voted against – 'undermines' the Scottish Parliament.
Mr Alexander however said the UK Government has 'been explicit about the need for businesses to have certainty', saying this is 'why the review has not considered repeal of the Act or any of its provisions'.
He said the UK Government has instead 'pledged to explore improvements in the way the Act's provisions operate', adding 'very real concerns' have been raised.
Following the UK's departure from the European Union, the then Tory UK government introduced the IMA in order to create a single market across the four nations of the UK.
The legislation however caused difficulties for the Scottish Government when it attempted to introduce a deposit return scheme for empty cans and bottles ahead of the rest of the UK.
In the wake of the review, the UK Government is promising changes, including the introduction of exclusions to the legislation, that have been agreed by all governments within a common framework.
As well as considering economic impacts, issues of environmental protection and public health will also be looked at for exclusions – with the UK Government saying this ensures a 'balance of factors is considered'.
Mr Alexander stressed the importance of having a 'well-functioning UK internal market' as part of the Government's 'ambition to improve economic growth for the benefit of businesses and people in all parts of our country'.
He added: 'Latest figures show that trade between the four nations of the UK is valued at £129 billion and that it is particularly important to the economies of Scotland, Wales, and Northern Ireland.'
But Mr Robertson insisted the IMA had been introduced by the previous Conservative government 'without the consent of any devolved government or Parliament'.
Speaking about the legislation, he added: 'It undermines the ability of the Scottish Parliament to use its powers to pursue devolved social and economic objectives in Scotland for the people to which it is accountable.
'It introduces radical new uncertainty as to the effect of laws passed by the Scottish Parliament and effectively provides a veto to UK ministers.
'Nothing set out in the UK Government's response to the review changes this position, which is completely unacceptable.
'The conclusion of the review falls well short of our stated position of repeal and replace the Internal Market Act, and indeed short of the legislative change required to mitigate the most damaging aspects of the operation of the IMA.
'It is important also to note that the Scottish Parliament has twice voted to repeal the Act – since it is fundamentally misconceived and incompatible with devolution.'
While he said the Scottish Government welcomes the UK Government's intention 'to address some of the most egregious issues with the function of the IMA exclusions process', he added that SNP ministers 'remain concerned that there is no clear vehicle to give meaningful effect to these changes, which work against our shared interests to promote growth, protect jobs and ensure seamless trade across the UK nations'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Minister 'weaponising' Savile will make Labour MPs queasy - but there's a bigger risk
Sometimes governments blindly idle into political fights and sometimes they go windmilling in with purpose. is most definitely the later of these two. The science secretary's reference to was no slip of the tongue. Ministers seem to believe has made a misjudgement in pledging to scrap internet safety laws, given the massive unease across the country about what children are viewing online. As a result, Kyle is trying to point at their position by stoking a spat with (some would say) inflammatory language that sucks up media attention. It's not exactly a new technique. Think back to 2023 and Labour did something very similar when it ran attack ads accusing of not wanting to lock up child abusers - in a bid to draw attention to the criminal justice system. Go even further back, and it's essentially the same strategy employed on the red Brexit bus in 2016 with its pledge to divert money from the EU to the NHS. All heavily disputable claims that are made to start a row and move the spotlight onto a politically convenient topic. But the risk inherent in tactics like this is that it makes some on your own side feel a little icky. The last politician to invoke Jimmy Savile as part of a political attack was when he accused of failing to investigate the serial child abuser when he was the country's head prosecutor. That led to the resignation of the then prime minister's top policy aide. Read more from Sky News: There will be plenty in who feel similarly queasy about a cabinet minister weaponising one of the country's most notorious paedophiles to lay into an opposition party. The bigger risk though is whether Peter Kyle will really emerge victorious from this fight. is going for the in part because it fits with his party's narrative around mainstream politics trying to silence the concerns of ordinary people. Those disenfranchised sections of society are a key group of voters that Reform are trying to reach. Whether they are outweighed by those put off the party by its recent pronouncements remains to be seen. But for now, this seems to be a fight that Nigel Farage is also keen to have.
Yahoo
5 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
US-Based geniant Expands International Footprint With Acquisition of London-Based Brand Experience Studio NewTerritory
Dallas, Texas & London, United Kingdom--(Newsfile Corp. - July 29, 2025) - Today, leading US-based experience consultancy, geniant, has announced its acquisition of NewTerritory, an award-winning UK-based design and brand experience studio founded by former Head of Design for Virgin Atlantic and LG Europe. The London-based team has gained international recognition through multi-sector, visionary projects for clients that include Delta Air Lines, Mercedes-Benz AG, Airbus and Coca-Cola. This move accelerates geniant's global growth strategy while directly addressing a fundamental need in business transformation - the ability to look across all interconnected customer and employee touchpoints, identify the moments that matter most, and then design and deliver next-generation experiences. "As more companies accept that the quality of their customer and employee experiences are key to marketplace success, the real challenge becomes identifying which moments to optimize first - and understanding why they matter," said David Lancashire, geniant's Chairman & Co-CEO. "NewTerritory's expertise in uncovering and shaping those Signature Moments that leave a lasting impression is a powerful addition to geniant's capabilities, strengthening our ability to guide companies toward what truly drives loyalty and impact." Commenting on the deal announcement, Luke Miles, Founder of NewTerritory, said: "Organizations face growing pressure to create distinctive, memorable experiences but often turn to partners unable to deliver at the intersection of creative vision, strategic insights and AI. What drew us to geniant was not just their mastery of these critical capabilities, but a shared belief that the current approach is broken, and that together we can help reimagine better workflows and experiences and actually bring them to life." geniant helps organizations see the big picture, bringing deep insight into customer needs together with a detailed understanding of internal workflows, through its integrated 'Insights, Experiences and AI-First' approach, delivering next-generation experiences. Insights: Proprietary research and analytics pinpoint critical moments that genuinely matter to customers and employees. Experiences: Elevating these moments into unified journeys across digital products, physical environments, and human interactions. AI-First: Guiding enterprises through IT modernization by embedding AI at the heart of products, workflows, and decision-making. Prove value quickly with targeted "lighthouse" projects that build momentum. Prioritize AI investments in alignment with clear business goals to achieve measurable results. Build an adaptive technology foundation that empowers leaders across the enterprise to launch new offerings, streamline operations, and scale with confidence. This cohesive approach enables brands to break free from the "experience echo chamber" and foster authentic, lasting customer and employee loyalty. -ENDS- For media information and editorial images, please contact: hello@ For high resolution copies of these images, please get in touch with the PR contact above: geniant, Chicago Studio To view an enhanced version of this graphic, please visit: New Territory, London Studio To view an enhanced version of this graphic, please visit: Luke Miles, Founder of NewTerritory To view an enhanced version of this graphic, please visit: About NewTerritory NewTerritory is a brand experience studio with capabilities spanning visioning, experience design, and communication. Based in London, the team, guided by data-driven insight, crafts seamless end-to-end experiences that build advocacy and deliver long-term value for brands. Founded by former head of design at Virgin Atlantic, Luke Miles, the studio is recognized for delivering game-changing brands and products within the travel, hospitality, and infrastructure industries. Visit to find out more. About geniant geniant is an experience consultancy helping organizations transform by uniting insights, customer and employee experiences, and AI-first technology. With a proven track record across diverse industries, geniant partners with enterprises to reimagine every touchpoint to deliver measurable business impact. Visit to learn more. To view the source version of this press release, please visit Sign in to access your portfolio
